Enterprise Value
779.8M
Cash
236.4M
Avg Qtr Burn
-13.07M
Short % of Float
12.32%
Insider Ownership
0.31%
Institutional Own.
74.39%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seladelpar (MBX-8025) Details Primary biliary cholangitis, Liver disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
MBX-2982 (GPR119 agonist) Details Hypoglycemia | Phase 2a Data readout |